Protect Your Bio-Identical Hormones Before—Not After!—They’re Taken Away

Protect Your Bio-Identical Hormones Before—Not After!—They’re Taken Away

The “National Academies of Sciences, Engineering and Medicine Health and Medicine Division” has announced1 an investigation titled Clinical Utility of Treating Patients with Compounded “Bioidentical Hormone Replacement Therapy”. The fact that this written title describing the investigation has quotation marks only around “Bioidentical Hormone Replacement Therapy” gives us a very large clue that from the start this investigation will be biased, as it can’t bring itself to fully recognize the name that has been used by physicians and the millions of individuals using this treatment since the 1980s.

Take Action to Protect Patient Access to Compounded Medications

Take Action to Protect Patient Access to Compounded Medications

PCCA members will be in D.C., April 9-10, for the 7th Annual ACT Legislative Conference, calling on lawmakers to support patient access to compounded medications. If you can’t join us at ACT, we need your help in contacting your Representatives now on these 2 opportunities to help patients. Please review the following information and contact your Congressional Representatives’ offices now.

Your Action Needed Today!

Your Action Needed Today!

On March 20th, the AANP filed a Citizen’s Petition with the FDA as the next step in challenging the FDA’s unprecedented attack on physician-prescribed compounded nutrients which is on track to reject fully 95 percent of the 300+ nominated natural ingredients often used by patients as compounded medications.

Congress Acts to Preserve Patient Access to Compounded Medications

Congress Acts to Preserve Patient Access to Compounded Medications

In a considerable win for patients who need compounded medications, the International Academy of Compounding Pharmacists (IACP), working with the DQSA Coalition, is very pleased to announce that the President has signed the Congressional Omnibus bill into law, H.R. 244, which provides funding through September 30, 2017, and includes language that addresses the Memorandum of Understanding, office-use, and pharmacy inspections.

Low Dose Naltrexone

Low Dose Naltrexone

Marie Antoinette’s quote is a great reminder that at times, new uses can be found with old things, such is the case with the drug Naltrexone. First synthesized as a competitive opioid antagonist in 1963, for many years research on Naltrexone remained dormant until

^
Font Resize
Contrast
X

Forgot Password?

Join Us

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.